Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Pfizer (NYSE:PFE) and maintained a $45 price target on the stock.
January 09, 2024 | 2:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen reaffirmed an Overweight rating on Pfizer with a $45 price target, indicating a positive outlook on the stock.
The reiteration of an Overweight rating by a reputable analyst suggests a positive sentiment towards Pfizer's stock performance in the short term. The maintained price target of $45 implies a potential upside from the current trading price, which could influence investor confidence and drive short-term price movement in a positive direction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100